NASDAQ:ACRS Aclaris Therapeutics (ACRS) Stock Price, News & Analysis $1.39 +0.04 (+2.96%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.34▼$1.4150-Day Range$1.01▼$1.4052-Week Range$0.59▼$10.15Volume402,131 shsAverage Volume1.24 million shsMarket Capitalization$99.05 millionP/E RatioN/ADividend YieldN/APrice Target$22.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Aclaris Therapeutics alerts: Email Address Aclaris Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.14 Rating ScoreUpside/Downside1,500.7% Upside$22.25 Price TargetShort InterestHealthy3.03% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.87Based on 18 Articles This WeekInsider TradingAcquiring Shares$2.75 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.77) to ($0.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.84 out of 5 starsMedical Sector235th out of 936 stocksPharmaceutical Preparations Industry104th out of 436 stocks 3.1 Analyst's Opinion Consensus RatingAclaris Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 1 buy rating, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageAclaris Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Aclaris Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.03% of the outstanding shares of Aclaris Therapeutics have been sold short.Short Interest Ratio / Days to CoverAclaris Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aclaris Therapeutics has recently decreased by 45.18%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAclaris Therapeutics does not currently pay a dividend.Dividend GrowthAclaris Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACRS. Previous Next 3.8 News and Social Media Coverage News SentimentAclaris Therapeutics has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Aclaris Therapeutics this week, compared to 2 articles on an average week.Search Interest23 people have searched for ACRS on MarketBeat in the last 30 days. This is an increase of 1,050% compared to the previous 30 days.MarketBeat Follows19 people have added Aclaris Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 1,800% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aclaris Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,750,797.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.40% of the stock of Aclaris Therapeutics is held by insiders.Percentage Held by Institutions98.34% of the stock of Aclaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aclaris Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Aclaris Therapeutics are expected to grow in the coming year, from ($0.77) to ($0.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aclaris Therapeutics is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aclaris Therapeutics is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAclaris Therapeutics has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aclaris Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agency5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.Click here to pay just $5 for a full year of Stealth Trades About Aclaris Therapeutics Stock (NASDAQ:ACRS)Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Read More ACRS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACRS Stock News HeadlinesJuly 23 at 4:25 AM | insidertrades.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Major Shareholder Acquires $23,562.28 in StockJuly 11, 2024 | marketbeat.com3 Beaten Down Pharmaceuticals With Catalysts for Higher PricesTrading volume spikes in beaten-down stocks often signal a bottom for prices investors can bank on. The problem is that beaten-down stocks are usually in that position for a good reason, so it helps if there is a catalyst for higher share prices in addition to the trading volume.July 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.July 11, 2024 | marketbeat.com3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices (ACRS)Beaten-down stocks offer value to investors, but not all are worth buying. This is a look at three biopharma at long-term lows with catalysts for higher prices.July 6, 2024 | insidertrades.comInsider Buying: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Major Shareholder Buys 123,017 Shares of StockJuly 2, 2024 | insidertrades.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Major Shareholder Buys $122,474.76 in StockJuly 2, 2024 | insidertrades.comBraden Michael Leonard Purchases 235,000 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) StockJuly 25 at 1:45 AM | americanbankingnews.comAnalysts Set Expectations for Aclaris Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:ACRS)July 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.July 24 at 11:33 AM | americanbankingnews.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Major Shareholder Braden Michael Leonard Purchases 17,716 SharesJuly 23 at 6:56 AM | americanbankingnews.comAclaris Therapeutics' (ACRS) Neutral Rating Reaffirmed at HC WainwrightJuly 23 at 5:04 AM | americanbankingnews.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Major Shareholder Braden Michael Leonard Acquires 130,317 SharesJuly 22, 2024 | markets.businessinsider.comH.C. Wainwright Keeps Their Hold Rating on Aclaris Therapeutics (ACRS)July 22, 2024 | americanbankingnews.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Rating of "Hold" from AnalystsJuly 16, 2024 | globenewswire.comAclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 MillionJune 25, 2024 | globenewswire.comRheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)June 6, 2024 | globenewswire.comAclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 10, 2024 | finance.yahoo.comEarnings Update: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Reported And Analysts Are Boosting Their EstimatesSee More Headlines Receive ACRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACRS CUSIPN/A CIK1557746 Webwww.aclaristx.com Phone(484) 324-7933Fax484-320-2344Employees100Year Founded2012Price Target and Rating Average Stock Price Target$22.25 High Stock Price Target$38.00 Low Stock Price Target$9.00 Potential Upside/Downside+1,500.7%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,480,000.00 Net Margins-248.28% Pretax Margin-249.46% Return on Equity-61.03% Return on Assets-46.97% Debt Debt-to-Equity RatioN/A Current Ratio6.74 Quick Ratio6.74 Sales & Book Value Annual Sales$31.25 million Price / Sales3.17 Cash FlowN/A Price / Cash FlowN/A Book Value$2.22 per share Price / Book0.63Miscellaneous Outstanding Shares71,260,000Free Float66,704,000Market Cap$99.05 million OptionableOptionable Beta0.27 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Neal S. Walker D.O. (Age 54)M.D., Co-Founder, President, Chairman & Interim CEO Comp: $955.69kDr. Joseph Monahan Ph.D. (Age 67)Chief Scientific Officer Comp: $600.02kMr. Kevin Balthaser (Age 36)Chief Financial Officer Mr. Matthew Rothman J.D.General Counsel & Corporate SecretaryDr. Jon Jacobsen Ph.D.Senior Vice President of ChemistryMr. James Loerop (Age 59)Chief Business Officer More ExecutivesKey CompetitorsTourmaline BioNASDAQ:TRMLTScan TherapeuticsNASDAQ:TCRXAC ImmuneNASDAQ:ACIUSolid BiosciencesNASDAQ:SLDBALX OncologyNASDAQ:ALXOView All CompetitorsInsiders & InstitutionsBraden Michael LeonardBought 17,716 shares on 7/22/2024Total: $23,562.28 ($1.33/share)Braden Michael LeonardBought 130,317 shares on 7/18/2024Total: $169,412.10 ($1.30/share)Braden Michael LeonardBought 123,017 shares on 7/5/2024Total: $141,469.55 ($1.15/share)Braden Michael LeonardBought 143,288 shares on 7/3/2024Total: $166,214.08 ($1.16/share)Braden Michael LeonardBought 107,434 shares on 7/1/2024Total: $122,474.76 ($1.14/share)View All Insider TransactionsView All Institutional Transactions ACRS Stock Analysis - Frequently Asked Questions How have ACRS shares performed this year? Aclaris Therapeutics' stock was trading at $1.05 at the start of the year. Since then, ACRS shares have increased by 32.4% and is now trading at $1.39. View the best growth stocks for 2024 here. How were Aclaris Therapeutics' earnings last quarter? Aclaris Therapeutics, Inc. (NASDAQ:ACRS) announced its quarterly earnings results on Tuesday, May, 7th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.04. The biotechnology company had revenue of $2.40 million for the quarter, compared to analyst estimates of $1.99 million. Aclaris Therapeutics had a negative trailing twelve-month return on equity of 61.03% and a negative net margin of 248.28%. What is Neal Walker's approval rating as Aclaris Therapeutics' CEO? 1 employees have rated Aclaris Therapeutics Chief Executive Officer Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among the company's employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are Aclaris Therapeutics' major shareholders? Top institutional shareholders of Aclaris Therapeutics include Concourse Financial Group Securities Inc.. Insiders that own company stock include Braden Michael Leonard, Neal Walker, Andrew N Schiff, Joseph Monahan, James Loerop, Douglas J Manion, Kevin Balthaser and Frank Ruffo. View institutional ownership trends. How do I buy shares of Aclaris Therapeutics? Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Aclaris Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aclaris Therapeutics investors own include TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Trevena (TRVN), AVEO Pharmaceuticals (AVEO) and Corbus Pharmaceuticals (CRBP). This page (NASDAQ:ACRS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
